Pharmacokinetics of praziquantel and pyrantel pamoate combination following oral administration in cats
- PMID: 29017390
- PMCID: PMC11129249
- DOI: 10.1177/1098612X17734065
Pharmacokinetics of praziquantel and pyrantel pamoate combination following oral administration in cats
Abstract
Objectives The pharmacokinetics of praziquantel and pyrantel pamoate has never been reported in cats. The present study was designed to establish the plasma concentration-time profile and to derive pharmacokinetic data for a combined formulation of praziquantel and pyrantel in cats, after a single, oral administration. Methods Twenty-two clinically healthy adult cats were used, each receiving a single oral dose of praziquantel (8.5 mg/kg) and pyrantel (100 mg/kg). Blood samples were collected at regular time points up to 48 h post-dosing. Plasma concentrations of praziquantel and pyrantel were measured using a liquid chromatography-mass spectrometry-high-throughput screening method. Results Clinical examination of all cats did not reveal any side effects after oral administration of these medications. The terminal half-life for praziquantel and pyrantel was 1.07 and 1.36 h, respectively. Praziquantel peak concentration (Cmax) was 1140 μg/ml, reached at 1.22 h. The plasma concentrations of pyrantel after oral administration were low with a mean Cmax of 0.11 μg/ml, reached at a Tmax of 1.91 h. Pyrantel showed a very limited absorption as pamoate salt, suggesting permanence and efficacy inside the gastrointestinal tract, where the adult stages of most parasitic nematodes reside. Conclusions and relevance Pyrantel showed a very limited absorption as pamoate salt. Praziquantel was rapidly absorbed following oral administration and the concentrations achieved suggest that praziquantel could be an effective and safe medication in cats. Although some resistance problems are arising as a result of their long use, these anthelminthic products can still play a major role in parasitic control, especially in geographical areas where the high cost of newer treatments or necessity of parenteral administration could decrease the number of treated animals.
Conflict of interest statement
This study was sponsored by Vim Spectrum, Hungary. LG is an employee of Vim Spectrum. The author meets the criteria for authorship as recommended by the International Committee of Medical Journal Editors and participated in the analysis and interpretation of the data.
Figures
References
-
- Riviere JE, Papich MG. Chemotherapy of parasitic diseases. In: Riviere JE, Papich MG. (eds). Veterinary pharmacology and therapeutics. 9th ed. Ames, IA: Wiley-Blackwell, 2009, pp 1053–1181.
-
- Echeverry DM, Giraldo MI, Castaño JC. Prevalence of intestinal helminths in cats in Quindío, Colombia. Biomedica 2012; 32: 430–436. - PubMed
-
- Little S, Adolph C, Downie K, et al.. High prevalence of covert infection with gastrointestinal helminths in cats. J Am Anim Hosp Assoc 2015; 51: 359–364. - PubMed
-
- Paul A, Tranquilli W. Ivermectin. In: Kirk RW. (ed). Current veterinary therapy. 10th ed. Philadelphia, PA: WB Saunders, 1989, pp 140–142.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous